Search

Displaying results 8081 - 8090 of 8415 in total
  1. Drug

    Setileuton

    go.drugbank.com/drugs/DB19550
    Investigational

    Setileuton has a monoisotopic molecular weight of 463.12 Da.

  2. Drug

    Ledaborbactam etzadroxil

    go.drugbank.com/drugs/DB21455
    Investigational

    Ledaborbactam etzadroxil has a monoisotopic molecular weight of 391.18 Da.

  3. Drug

    Azetukalner

    go.drugbank.com/drugs/DB21551
    Investigational

    Azetukalner has a monoisotopic molecular weight of 368.23 Da.

  4. Drug

    Icovamenib

    go.drugbank.com/drugs/DB21669
    Investigational

    Icovamenib has a monoisotopic molecular weight of 566.28 Da.

  5. Drug

    Indium In-111 oxyquinoline

    go.drugbank.com/drugs/DB09473
    Approved

    It is therefore useful in nuclear medicine, and is used in the labeling of leukocytes for localization of processes to which leukocytes migrate, such as those associated with abscesses or other infections

  6. Drug

    Otamixaban

    go.drugbank.com/drugs/DB06635
    Investigational

    It is currently being developed by the French pharmaceutical company Sanofi-Aventis as a treatment for acute coronary syndrome.

  7. Drug

    ALS-08

    go.drugbank.com/drugs/DB05705
    Experimental

    ALS-08 is a proprietary creatine-derivative that is being developed as a potential therapeutic for amyotrophic lateral sclerosis (ALS). It is being developed by Avicena Group, Inc.

  8. Drug

    Fenpyroximate

    go.drugbank.com/drugs/DB16164
    Investigational

    Fenpyroximate is under investigation in clinical trial NCT02533336 (The Effectiveness of Non-pyrethroid Insecticide-treated Durable Wall Liners as a Method for Malaria Control in Endemic Rural Tanzania

  9. Drug

    Zandatrigine

    go.drugbank.com/drugs/DB19051
    Investigational

    Zandatrigine is under investigation in clinical trial NCT05226780 (Extension Study to Evaluate How Safe and Tolerable NBI-921352 Is as an Adjunctive Therapy for Participants With SCN8A-DEE).

  10. Drug

    Fontolizumab

    go.drugbank.com/drugs/DB05111
    Investigational

    Fontolizumab (marketed under the trade name HuZAF™) is a humanized monoclonal antibody which is used as an immunosuppressive drug to treat Crohn's disease.